Key indicators: single-crystal X-ray study; T = 295 K; mean (C-C) = 0.003 Å; R factor = 0.055; wR factor = 0.172; data-to-parameter ratio = 17.5.
In the title compound, C 18 H 22 ClNO 3 , the dihedral angle between the benzene ring and the conjugated part of the enaminone ring is 55.19 (9) . The ester substituent makes a dihedral angle of 81.0 (2) with this latter moiety. The crystal structure features N-HÁ Á ÁO and weak C-HÁ Á ÁO intermolecular interactions.
Related literature
Our research on enaminones has led to several compounds possessing anticonvulsant properties, see: Edafiogho et al. (1992) ; Eddington et al. (2003) ; Scott et al. (1993 Scott et al. ( , 1995 .
Experimental
Crystal data Table 1 Hydrogen-bond geometry (Å , ). tert-Butyl 4-(4-chloroanilino)-6-methyl-2-oxocyclohex-3-enecarboxylate M. S. Alexander, H. North, K. R. Scott and R. J. Butcher
Comment
Our research on enaminones has led to several compounds possessing anticonvulsant properties (Edafiogho et al., 1992; Eddington et al., 2003; Scott et al., 1993 Scott et al., , 1995 . The present work is part of a structural study of enaminones. Our group has extensively studied the effects of modification of the enaminone with substitutions at the methyl ester, ethyl ester, and without the ester group. We synthesized a series of carbo-tert-butoxy esters to evaluate the effect of added bulk and lipophilicity to the ester functionality. These compounds showed significant anticonvulsant activity. The title compound, tert-butyl-4-(4-chlorophenlyamino)-6-methyl-2-oxocyclohex-3-enecarboxylate is highly active, with activity at <100 mg kg -1
. The compound was active in maximal electroshock seizure evaluation (MES) in mice, indicative of protection against tonic-clonic convulsions in humans (1/4 rats protected at 1 h, 2 h and 4 h post dose at 50 mg kg dose). Toxicity tests showed no toxicity in rats (oral) up to 4 h at 50 mg/kg per dose. The MES study in mice showed 1/1 animals were protected at 300 mg/kg at 30 minutes. In 4 h testing, 3/3 animals were protected at 100 mg/kg and 1/1 animals protected at 300 mg/kg dose.
In toxicity studies, at 15 min, 2/8 mice (ip = interperitoneal) showed toxicity at 500 mg/kg dose. A 2 h MES protection test in mice (ip) displayed 3/8 animals protected at 85 mg/kg dose, 4/8 animals protected at 100 mg/kg, and 7/8 animals were protected at 170 mg/kg (optimum dose). In mice, the MES ED50 (median effective dose) of 106.34 mg kg -1 and TD50
(median toxic dose) of 500 mg kg -1 TD, 95% confidence inteval. The scMET (subcuntaneous metrazole) test showed no protection at 250 or 500 mg/kg during a 2 h range.
In view of the therapeutic interest in this compound its structure was determined. The conformation adopted by the molecule is such that the dihedral angle between the phenyl ring and conjugated part of the enaminone ring is 55.19 (9)°.
The ester substituent makes a dihedral angle of 81.0 (2)° with this latter moiety. The crystal structure is held together by strong N-H···O and weak C-H···O intermolecular interactions.
Experimental 4-Carbo-tert-butoxy-5-methylcyclohexane-1,3-dione (6. 11 g, 27 mmol), mp 145-146° C (lit. mp 130-131.5°C),7 and 4-chloroaniline (4.21 g, 33 mmol) were added to a mixture of absolute EtOH (100 ml) and EtOAc (100 ml), and the solution was refluxed and stirred for 6 h. Evaporation under reduced pressure yielded a yellow solid which was recrystallized from Figures Fig. 1 . Diagram of tert-butyl-4-(4-chlorophenlyamino)-6-methyl-2-oxocyclohex-3-enecarboxylate showing atom labeling scheme. Thermal ellipsoids drawn at the 30% probability level. 
